Ownership history in ORBIMED ADVISORS LLC · 84 quarters on record
This page tracks every 13F SEC filing in which ORBIMED ADVISORS LLC reported a position in Pfizer Inc. COM (PFE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | ADDED | 1,652,900 | +1,152,900 | +230.6% | 0.84% | $41.2M | $24.49 |
| 2025 Q3 | REDUCED | 500,000 | -3,350,200 | -87.0% | 0.30% | $12.7M | $24.63 |
| 2025 Q1 | ADDED | 3,850,200 | +3,350,200 | +670.0% | 2.33% | $97.6M | $23.63 |
| 2025 Q1 | ADDED | 500,000 | +250,000 | +100.0% | 0.30% | $12.7M | $23.63 |
| 2024 Q4 | UNCHANGED | 250,000 | — | 0% | 0.14% | $6.6M | $24.33 |
| 2024 Q2 | REDUCED | 250,000 | -250,000 | -50.0% | 0.14% | $7.0M | $24.92 |
| 2023 Q4 | REDUCED | 500,000 | -893,600 | -64.1% | 0.29% | $14.4M | $24.88 |
| 2022 Q4 | REDUCED | 1,393,600 | -1,205,400 | -46.4% | 1.37% | $71.4M | $42.37 |
| 2022 Q3 | REDUCED | 2,599,000 | -145,000 | -5.3% | 2.11% | $113.7M | $35.87 |
| 2022 Q2 | REDUCED | 2,744,000 | -1,161,500 | -29.7% | 2.61% | $143.9M | $42.65 |
As of 2025 Q4 — sorted by position size